Is SMR a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Regulatory progress and design certification, with revenue (ttm) at ~$10.7 million; Q2 2026 revenue ~$75,000. The bear case rests on nuScale is early-stage and largely pre-revenue, with about $10.7 million of trailing revenue and a trailing net loss near $416 million, so it depends on its cash (about $1.07 billion at mid-2026) and periodic capital raises that can dilute shareholders. Analysts covering it are spread from $6.00 to $20.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. NuScale is early-stage and largely pre-revenue, with about $10.7 million of trailing revenue and a trailing net loss near $416 million, so it depends on its cash (about $1.07 billion at mid-2026) and periodic capital raises that can dilute shareholders. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $6.00, +2.9% from the $5.83 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Regulatory progress and design certification. NuScale is among the few SMR developers to clear key US Nuclear Regulatory Commission review milestones for its reactor design, a meaningful and hard-to-replicate regulatory advantage. The most optimistic analyst target on SMR is $20.00, +243.1% from the $5.83 price. That figure is only reachable if this thesis works close to its best case.

NuScale is early-stage and largely pre-revenue, with about $10.7 million of trailing revenue and a trailing net loss near $416 million, so it depends on its cash (about $1.07 billion at mid-2026) and periodic capital raises that can dilute shareholders. It has not yet brought a commercial SMR online or signed a binding plant contract, and an earlier flagship deployment project was cancelled over cost concerns, a stark reminder that SMR economics are unproven at scale. Nuclear projects face long timelines, heavy regulation, financing hurdles, and public and political sensitivity; the RoPower project in Romania, for example, still needs financing. Competition includes other SMR developers and alternative clean-power sources. The stock is highly volatile and trades on milestone news, government policy, and energy and AI-power sentiment: it fell about 64% in 2026 through October 16 and about 88% over one year. An investment could lose substantial value if deployments do not materialize. The most pessimistic published target is $6.00, +2.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Early-stage small modular nuclear reactor developer with an NRC-reviewed design; a speculative bet on SMRs delivering carbon-free baseload.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Regulatory progress and design certification) stalling in the reported numbers rather than in the narrative, the risk above (nuScale is early-stage and largely pre-revenue, with about $10.7 million of trailing revenue and a trailing net loss near $416 million, so it depends on its cash (about $1.07 billion at mid-2026) and periodic capital raises that can dilute shareholders) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

NuScale Power trades under the ticker SMR, listed on the New York Stock Exchange. The ticker reflects its small modular reactor focus. The company is headquartered in Portland, Oregon, and is affiliated with engineering firm Fluor. It trades during US market hours and is available at every major US brokerage.

NuScale develops small modular nuclear reactors (SMRs), compact factory-built reactor modules pitched as a safer, more standardized alternative to large conventional nuclear plants. Its design has cleared key US Nuclear Regulatory Commission review milestones. It targets carbon-free baseload power for utilities, governments, and large power users, and is still pre-commercial.

No. NuScale is early-stage and largely pre-revenue, with about $10.7 million of trailing twelve-month revenue and a trailing net loss of about $416 million; the second quarter of 2026 alone lost about $47.5 million on $75,000 of revenue. It relies on its cash balance (about $1.07 billion at mid-2026) and periodic capital raises, which can dilute existing shareholders. Profitability would depend on commercial deployments that have not yet occurred.